BRAF and neuroblastoma: Molecular research based on transcriptomic and/or genetic studies has contributed to the development of targeted therapies for colon cancer, such as those limiting angiogenesis through acting on vascular endothelial growth factor (anti-VEGF), targeting EGFR (Epidermal Growth Factor Receptor) and RAS (rat sarcoma) mutations, as well as KRAS (Kirsten RAS), NRAS (neuroblastoma RAS), BRAF (B-Raf proto-oncogene, serine/threonine kinase), MEK (mitogen-activated protein kinase kinase), and TNFA (Tumor Necrosis Factor A) inhibitor therapies.